Kidney Disease News and Research

RSS

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

Study evaluates safety and effectiveness of Diamondback device for heart attacks

Drilling through concrete to create an opening may sound more like construction than medicine, but the approach is similar to what researchers at Orlando Regional Medical Center (ORMC) are doing in a clinical trial to evaluate a device that breaks through hardened coronary arteries, in an effort to prevent heart attacks and relieve chest pain.

23 Nov 2011

Diaverum signs joint venture agreement with Nazer Group

November 2011: Diaverum, one of the world´s largest independent renal care providers, has signed a joint venture agreement with Nazer Group, a Saudi Arabian Holding Company with major investments in the medical sector including Bupa Arabia.

22 Nov 2011

New blood spot analysis method can diagnose range of clinical conditions

Scientists have developed a rapid method that can be used to simultaneously screen patients for a range of genetic and acquired clinical conditions from a single dried blood spot.

17 Nov 2011

Mycophenolate mofetil superior to azathioprine for lupus nephritis

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

17 Nov 2011

Amgen receives EC approval to extend therapeutic indications for Vectibix

Amgen today announced that the European Commission (EC) has approved a variation to the marketing authorization for Vectibix (panitumumab) to include indications for the treatment of patients with wild-type KRAS metastatic colorectal cancer (mCRC) in first-line in combination with FOLFOX and in second-line in combination with FOLFIRI in patients who have received first-line fluoropyrimidine-based chemotherapy.

16 Nov 2011

Amgen's XGEVA delays onset of bone metastases in men with prostate cancer

Amgen announced today the publication of results from a Phase 3 trial (the '147 study) that evaluated XGEVA (denosumab) for use in preventing or delaying the onset of bone metastases in men with nonmetastatic castration-resistant prostate cancer.

16 Nov 2011

New non-invasive measurement may predict people at risk of heart failure

A new study from researchers at the Perelman School of Medicine at the University of Pennsylvania and collaborators at various institutions, presented at the 2011 American Heart Association Scientific Sessions, shows that a novel, non-invasive measurement of arterial wave reflections may be able to predict who is most at risk for heart failure.

15 Nov 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.

14 Nov 2011

Intensive therapy can preserve kidney function in patients with type 1 diabetes

People with type 1 diabetes are at high risk of developing kidney disease, but no therapies are proven to prevent impaired kidney function in these patients. In the Diabetes Control and Complications Trial (DCCT), Ian de Boer, MD and his team looked to see if intensive diabetes therapy aimed at reducing blood sugar as close to the normal range as possible might protect type 1 diabetics' kidney function. The study's results were presented during the American Society of Nephrology's Annual Kidney Week.

14 Nov 2011

Maintaining normal blood glucose levels prevents long-term kidney complications

Maintaining good glucose control early in the course of type 1 diabetes could lessen the long-term risk of kidney disease, as measured by a common test of kidney function.

14 Nov 2011

New information on kidney-related policies in the U.S.

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on kidney-related policies in the United States.

14 Nov 2011

NIDDK-funded study to develop approaches for chronic kidney disease management

Cleveland Clinic nephrologist Joseph Nally Jr., M.D., has been awarded a three-year, $720,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to study and develop approaches for disease management for patients with chronic kidney disease.

14 Nov 2011

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease.

14 Nov 2011

Salt – is it bad for the heart? Debate continues

Salt or high sodium intake in diet has drawn attention of researchers for a while now. The U.S. Food and Drug Administration held a day-long hearing today, discussing strategies to help Americans cut the salt from their diets as a latest attempt to curb sodium in the American diet.

13 Nov 2011

Updates on dietary benefits and dangers in kidney disease patients

Two studies presented during the American Society of Nephrology's Annual Kidney Week provide new information on dietary benefits and dangers in kidney disease patients.

11 Nov 2011

Diabetics with kidney failure should not lower their hemoglobin A1C levels

Two separate studies presented during the American Society of Nephrology's Annual Kidney Week agree that diabetics with kidney failure shouldn't lower their blood glucose levels as much as diabetics without kidney failure.

11 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

Pediatric racial minorities less likely to get kidney transplants

Among children with kidney disease, certain races are less likely to get kidney transplants and are more likely to die than other races, according to two studies from Emory University that were presented during the American Society of Nephrology's Annual Kidney Week.

11 Nov 2011